【文档说明】肌松药的临床应用课件.ppt，共(79)页，311.296 KB，由小橙橙上传

转载请保留链接：https://www.ichengzhen.cn/view-234304.html

以下为本文档部分文字说明：

第八章肌松药的临床应用1目的与要求掌握:肌松药的应用原则以及残留肌松作用的判断熟悉：肌松药的不良反应,影响肌松药作用的因素肌松药的麻醉期间的应用了解：神经肌肉传递功能监测2Key◼Hypnosis◼Analgesia◼Amnesia

◼Relaxation3HistoryIn1942GriffithandJohnsonsuggestedthatd-tubocurarine(dTc)Succinylcholine,introducedbyThesleffandFol

desetalin1952In1967BairdandReidfirstreportedpancuroniumintheearly1980softwonewmusclerelaxantsofintermediateduration

atracuriumandvecuroniumTheearly1990switnessedpipecuronium,doxacurium,mivacuriumandrocuroniumAnatracuriumisomer,cisatracuriumintro

ducedin19964ClinicalUseTrachealintubationOperationICUCureofspasticity5MolecularFeaturesNeuromuscularblockingdrugsarequaternaryammoniumcompound

sNearlyallmusclerelaxantscontaintwopositivecharges6Musclerelaxantsaregenerallyquitewater-solubleThewaterso

lubilityofrelaxantsinhibitsuptakeintohepatocytesMetabolismand/orexcretionintheliverisusuallynotamajorpathw

ayofeliminationThemusclerelaxantsareeasilyexcretedbyglomerularfiltrationintheurine7ClassDepolarizingdrugsuccinylcholineImbretil（己氨胆碱、氨酰胆碱）8PH

ARMACOLOGYOFSUCCINYLCHOLINERapidhydrolysisbypseudocholinesterase假胆碱酯酶Factorsloweringpseudocholinesteraseconcentrationliverdiseas

ePregnancyBurnsoralcontraceptivesmonoamineoxidaseinhibitorscytotoxicdrugsneoplasticdiseaseanticholine

sterasedrugs胆碱酯酶抑制剂9CardiovascularEffectsstimulatesnicotinicreceptorsonbothsympatheticandparasympatheticgangliaandmuscarinicreceptor

sinthesinusnodeoftheheartInlowdoses,bothnegativeinotropicandchronotropic（负性变力、变频）responsesmayoccur.T

hesecanbeattenuatedbyprioradministrationofatropineWithlargedoses,positiveresponses.cardiacarrhythmias10SinusBradycardiawithhighsympatheti

ctone,suchaschildreninadultsandappearsmorecommonlyafteraseconddoseofthedrugisgivenapproximately5minutesafterthefi

rstpreventedbythiopental,atropine,ganglion-blockingdrugs,andnondepolarizingmusclerelaxants11Nodal(Junctio

nal)Rhythmssuppressingthesinusmechanismandallowingtheemergenceoftheatrioventricularnodeasthepacemakerpreventedbypriorad

ministrationofdTc12VentricularArrhythmiaslowersthethresholdoftheventricletocatecholamine-inducedarrhythmias

Circulatingcatecholamineconcentrationsincrease4-foldandpotassiumincreasesbyone-thirdOtherstimuli,suchasendotrachealintubation,

hypoxia,hypercarbia,andsurgery,areprobablyadditivetotheeffectofsuccinylcholine13ComplicationsHyperkalemiaBurnsTraumaClosedHeadInjuryIntra-Abdomi

nalInfectionsRenalFailureMetabolicAcidosis14IncreasedIntraocularPressureIncreasedIntragastricPressurePregnancyAscitesBowelobstr

uctionHiatusherniaIntracranialPressureMusclePains15NondepolarizingdrugSteroidalCompoundsPancuronium,Pipecuronium,

Vecuronium,RocuroniumandRapacuronium无组胺释放作用,主要经肾排泄，可松弛迷走神经松弛迷走神经中度Pancuronium,Rapacuronium轻度Rocuronium无Pipecuronium,Vecuron

ium16亲脂/亲水的水平决定肝脏摄取亲脂性强Vecuronium,RocuroniumandRapacuronium中短效、效能低、作用快、肝脏摄取代谢比例大，Vecuronium30~40%经肝去乙酰基代谢亲脂性弱Pancuronium长效、效能高、作用

慢、肝脏摄取代谢比例小，15~20%经肝代谢17Benzylisoquinolinium（苄基异喹啉）Compoundsd-Tubocurarine,Metocurine，Doxacurium，Atracurium，Cisatracuriumand

Mivacurium有组胺释放作用，可经肾排泄，不松弛迷走神经组胺释放作用显著d-Tubocurarine中度Metocurine甲筒箭毒轻度Atracurium，Mivacurium无Doxacurium，Cisatracuri

um给予组胺受体(H1和H2受体)阻滞药18ClassificationbyDurationofActionLong-ActingRelaxantsRelaxantsofIntermediateDurationShort-ActingRelaxants19Long-Acting

Relaxantsd-Tubocurarine,Metocurine，Doxacurium，Pancuronium，Pipecuronium，Gallamine3~6min起作用1.5~2倍ED95剂量插管80~120min肌颤搐恢复25%需谨

慎拮抗绝大部分经肾以原型排泄20RelaxantsofIntermediateDurationVecuronium,Rocuronium，Atracurium，Cisatracurium2~2.5min

起效维持30~60min45~90min95%肌颤搐恢复Vecuronium,Rocuronium经肝、肾双通道排泄Atracurium,CisatracuriumHofmann效应21Short-ActingRelaxantsM

ivacurium2min起效维持12~20min25~35min95%肌颤搐恢复血浆假性胆碱酯酶催化水解22Rapacuronium1min起效维持15~20min25~50min95%肌颤搐恢复

经胆汁、肾排泄代谢产物仍有活性可有蓄积作用23PharmacokineticsandPharmacodynamics242526DosageforTrachealIntubationdosageinthera

ngeoftwotothreetimestheED95isusuallygivenwithin1to3minutesIfthetracheahasalreadybeenintubatedwithoutarelaxantorwithsuccinylcholineandthe

purposeissimplytoproducesurgicalrelaxation,adoseslightlylessthantheED9527MaintenanceDosageSupplemental(maintenance)dosesofnondepolari

zersrangefrom20to30percentoftheinitialdoseinthecaseoflong-actingdrugsto35to50percentoftheinitialdose

inthecaseofintermediate-andshort-actingrelaxants28ControlofDepthofNeuromuscularBlockadetomaintain90to95percentblockofthetwi

tch(onetwitchvisibleonTOFstimulation)Infusiondosageisusuallydecreasedbyabout30to50percentinthepresenceofpotentinhaledanestheticsR

elaxationisgenerallyinadequateformostsituationsifallfourresponsesareclearlyvisibleorpalpableduringTOFmon

itoring29Ifoneortworesponsesarevisibleorpalpable,relaxationshouldbesufficientforabdominalsurgeryunderadequatedepthofanesthesiaIfo

nlyonetwitchisfaintlyvisibleorpalpable,relaxationshouldbedeepenoughtopermitintubationofthetracheaunderalready-establis

hedgeneralanesthesia30DosageforPrimingasmallsubparalyzingdoseofthenondepolarizer(about20%oftheED95orabout10%ofth

eintubatingdose)begiven2to4minutesbeforegivingasecondlargedosefortrachealintubation.Thisprocedure,termedpriming31hasbeenshowntoaccelerate

theonsetofblockofmostnondepolarizingrelaxantsbyabout30to60secondswiththeresultthatintubationcanbeperformedwith

inapproximately90secondsfollowingtheseconddoseRocuroniumandRapacuronium起效快不需预给量5倍ED95剂量以上的初始量后不需预给量32Pan

curoniumDosage(mg/kg)ClinicalDuration(min)ED950.06-0.07Intubation(att=+2–3min)0.08-0.1260-120Relaxation(N2O/O2)0.05-0.0630-60Relaxation(Vapor)0.033

0-60Maintenance0.01-0.01530-4033stimulationofthesympatheticnervoussystemusuallycauseanincreaseinheartrate,bloodpressure,andcardiacou

tputPancuroniumisclearedlargelybythekidneyAsmallamount(10–20%)isdeacetylatedatthe3-positionintheliver

34PipecuroniumDosage(mg/kg)ClinicalDuration(min)ED950.04-0.05Intubation(att=+2–3min)0.08-0.1280-120Relaxation(N2O/O2)0.04-0.0640-6

0Relaxation(Vapor)0.2-0.340-60Maintenance0.005-0.0130-4535pipecuroniumdoesnotblockautonomicganglia,nordoesitreleasehistamineThemajorexcretorypath

wayisthekidneyOnlyaverysmallamountofthedrug(5%)maybedeacetylatedatthe3-position36VecuroniumDosage(mg/kg)ClinicalDurat

ion(min)ED950.5Intubation(att=+1.5–3min)0.1-0.245-90Relaxation(N2O/O2)0.0525-40Relaxation(Vapor)0.03

-0.0425-40Maintenance0.01-0.0215-30Infusion0.8-2.0mg/kg/min37morefaciletrachealintubationwithnondepolarizerseasieradministra

tionbyinfusionformaintenanceofblockadeduringsurgeryfasterandmorecompleteantagonismofresidualblockadeattheendofthe

caselackofcardiovascularresponsesthroughoutawideclinicaldoserangefromonetoeighttimestheED95theliveristheprinc

ipalorganofeliminationforvecuronium38RocuroniumDosage(mg/kg)ClinicalDuration(min)ED950.3-0.4Intubation(att=+60–9

0s)0.6-1.035-75Relaxation(N2O/O2)0.3-0.430-40Relaxation(Vapor)0.2-0.330-40Maintenance0.1-0.1515-25Infusion8-12

mg/kg/min39fasteronsetItisseventoeighttimeslesspotentthanvecuroniumrocuroniumproducespainoninjectionRocuroniumiseliminatedprimarilybytheliv

er,withasmallfraction(10%)eliminatedintheurine40RapacuroniumDosage(mg/kg)ClinicalDuration(min)ED951.0-1.3Intubation(att=+60–90s)1.5-2.51

5-35Relaxation(N2O/O2)1.0-1.515-20Relaxation(Vapor)0.6-1.015-20Maintenance0.2-0.515-20Infusiona12→9m

g/kg/minaCumulationandslowedrecoverytendtodevelop.41lowpotency(ED901.15mg/kg),afastonset，andshort-to-inter

mediatedurationlittlecardiovasculareffectThedoseof3mg/kgwasassociatedwithanincreaseofplasmahistamineRenalexcretionamountsto22perce

ntofanadministereddoseitispossiblethatitsprincipalrouteofeliminationmaybeviatheliver42AtracuriumDosage(mg/kg)Clini

calDuration(min)ED950.23Intubation(att=+2–3min)0.5-0.630-45Relaxation(N2O/O2)0.3-0.430-45Relaxation(Vapor)0.2-0.330-45Maintenance0.1-0.1515

-20Infusion4-12mg/kg/min43Hofmanneliminationdosesofmorethan0.5mg/kg(morethantwotimesED95)causethereleaseofhistamineathig

hdosage44CisatracuriumDosage(mg/kg)ClinicalDuration(min)ED950.05Intubation(att=+1.5–3min)0.15-0.240-75Relaxation(N2O/O2)0.0530-45Relaxation(Vapor

)0.03-0.0430-45Maintenance0.01-0.0215-20Infusion1-2mg/kg/min45Cisatracuriumisaboutfourtimesmorepotentthanatracuriumandhasminimalcardiova

scularsideeffectsintermediatedurationofactionHofmannelimination46MivacuriumDosage(mg/kg)ClinicalDuration(mi

n)ED950.07-0.08Intubation(att=+2.0–3.0min)0.2-0.2515-20Relaxation(N2O/O2)0.110-15Relaxation(Vapor)0.0810-15Maintenance0.05-0.15-10Infusion3-15

(average6)mg/kg/min47hydrolyzedbyplasmacholinesteraseTheshortdurationofactionenablesmaintenanceofrelaxationbycontinuousinfusionrapidinjectionofdo

sesof0.2to0.25mg/kgcausehistaminerelease48非去极化肌松药的复合应用前后复合应用长时效肌松药后加用中时效或短时效肌松药,前者使后者的作用时效延长短时效肌松药后加用长时效或中时效肌松药，前者将使后者的作用时效缩短49同时复合应用

化学结构为同一类的两肌松药复合应用其作用相加不是同一类的两肌松药复合应用其作用协同50影响肌松药的药代动力学因素增加肌松药与蛋白的结合量,可增加其在体内分布容积，延缓其由肾排泄增加细胞外液量可增加肌松药在体内分布容积肝疾病引起体液潴留可

增加肌松药分布容积，肝脏功能下降可引起经肝脏代谢消除延缓，作用时效延长。肾功能衰竭病人不宜应用经肾排泄的肌松药51影响肌松药的药效动力学因素水、电解质和酸碱平衡呼吸性酸中毒增加氯筒箭毒碱和泮库溴铵的肌松作

用,且使其作用不易为新斯的明拮抗代谢性酸中毒抑制新斯的明拮抗上述两肌松药低钾血症和高钠血症可增强非去极化肌松药的作用低钙血症和高镁血症减少乙酰胆碱释放，增强非去极化肌松药作用52低温低温可以减

少肌肉的血流量,也可降低血浆蛋白结合肌肉松弛药的能力，使药物不易从神经肌肉接头部位转运至肝肾等器官代谢和排泄低温也影响肝脏和肾的血流量，降低代谢酶的活性低温还可影响乙酰胆碱的合成、释放，并能影响神经肌肉接头部位的敏感性53年龄新生儿体液量相对较大,分布容

积增加，消除半衰延长，因此追加次数应减少老年人体液量减少和肾排泄减慢，肌松药用量应减少神经肌肉疾病重症肌无力病人用药应十分谨慎肌无力综合征病人对去极化肌松药和非去极化肌松药都十分敏感肌强直综合征病人易发生术

后呼吸抑制54假性胆碱酯酶异常肝疾病、饥饿、妊娠末期及产褥期,此酶量减少或活性降低有机磷、六甲溴铵、新斯的明、单胺氧化酶抑制剂和某些抗癌药均可抑制该酶活性非典型性假性胆碱酯酶是由于遗传上的缺陷引起酶性质异常55药物

相互作用吸入全麻药吸入麻醉药增强非去极化肌松药作用的顺序是,最强为异氟烷、恩氟烷和地氟烷，其次是氟烷，最弱为氧化亚氮吸入麻醉药增强长时效非去极化肌松药如氯筒箭毒碱、泮库溴铵和哌库溴铵的作用比较明显，1/2-1/356吸入麻醉药对中时效非去极化肌松药如维

库溴铵和阿曲库铵的增强作用较弱,仅减少其药量的1/4吸入全麻药对去极化肌松药的影响相对较弱，其中以异氟烷的作用最强恩氟烷和异氟烷可促使琥珀胆碱较早演变为II相阻滞57局麻药大剂量局麻药本身就可阻滞神经肌肉接头较小剂量的局麻药能增强

非去极化肌松药和去极化肌松药作用58机制局麻药作用于接头前膜,减少乙酞胆碱囊胞的含量直接作用于接头后膜阻断钠通道，从而降低接头后膜对乙酞胆碱的敏感性可直接作用于肌纤维膜的离子通道，降低肌肉的收缩能

力抑制血浆假性胆碱酯酶的活性，使琥珀胆碱和米库氯铵的分解减慢，时效延长59抗心律失常药奎尼丁具有局部麻醉作用,可与非去极化肌松药和去极化肌松药产生协同作用，增强肌松药的强度和作用时效-受体阻滞药、钙通道阻滞药有可能影响神经肌肉接头的离子传导而增强肌松药作用60抗生素多粘菌素

的神经肌肉接头阻滞作用是所有抗生素中最强者,其效应逆转困难，钙离子和新斯的明对其拮抗的效应均很差氨基甙类抗生素中以新霉素和链霉素抑制神经肌肉传递的功能最强，还有妥布霉素、庆大霉素，丁胺卡那霉素，均可增强

非去极化肌松药和去极化肌松药作用61机制有接头前和接头后双重效应。作用于接头前膜有类似镁离子作用,影响乙酞胆碱的释放。作用于接头后有膜稳定作用。该类药物的神经肌肉接头阻滞作用可被钙离子和抗胆碱酯酶药部分拮抗林可霉素和氯霉素增强非去极化肌松

药的效应，而对去极化肌松药的效应影响很小。其作用机制同样涉及接头前和接头后双重作用，并可部分被钙和新斯的明拮抗62抗惊厥药及精神药苯妥英钠与泮库溴铵、氯二甲箭毒和维库溴铵合用时,可影响后者的肌肉松弛效应，

但对氯筒箭毒碱及阿曲库按无影响锂离子可取代体内的钾离子和钠离子，产生低钾血症和增强非去极化阻滞。对用锂治疗的躁狂抑郁症病人，泮库溴铵和琥珀胆碱的效应增强63肌松药的拮抗机制使乙酰胆碱在神经肌肉接头部位的浓度相对提高,使更多的胆碱受体从与肌松药结

合状态中解离出来而使神经肌肉接头恢复正常增加乙酰胆碱浓度或延长乙酰胆碱作用时间，均能拮抗非去极化肌松药的作用64抗胆碱酯酶药新斯的明、吡啶斯的明和依酚氯铵使较多的乙酰胆碱在神经肌肉接头部位积聚,与非去极化肌松药竞争受体。新斯的明还可作用于接头前膜增

加乙酰胆碱释放量，且可直接兴奋胆碱受体钾通道阻滞剂4-氨基吡啶延长突触前神经的去极化作用，增加神经内Ca2+，从而增加乙酰胆碱释放量和延长乙酰胆碱释放时间为消除抗胆碱酯酶药所引起的毒蕈碱样不良反应，常需伍用抗胆碱药，如阿托品或格隆溴铵65

时机肌松药应用达其维持效果后有微弱呼吸动作TOFratiotomorethan0.7单次肌颤搐刺激恢复25%以上66剂量neostigmine0.02mg/kg-0.04mg/kg＋阿托品0.01mg/kg-0.02mg/kg格隆溴铵7mg/kg与新斯的

明0.035~0.07mg/kg合用可减少心率变化所引起的危险,这适用于心肌缺血和心脏瓣膜疾病病人67影响抗胆碱酯酶药的作用酸碱和电解质失衡呼吸性酸中毒不仅加强非去极化肌松药的阻滞作用,且影响抗胆碱酯酶药的作用。当动脉血二

氧化碳分压（PaCO2）超过50mmHg时，抗胆碱酯酶药几乎不可能拮抗残余肌松代谢性碱中毒、低钾血症和高镁血症时，残余肌松也同样难以为抗胆碱酯酶药所逆转68低温肌松药难以从神经肌肉接头部移出抗胆碱酯酶药也难以进人神经肌肉接头老年人应用抗胆碱酯酶药应谨慎,

尤其是对应用了心血管系统药物的病人，如洋地黄、-受体阻滞药和三环类抗抑郁药的病人，抗胆碱酯酶药易引起心动过缓和心律紊乱69神经肌肉传递功能监测监测肌松药的起效、维持和消退科学合理正确地使用肌松药,减少不良反应的发生及时使用拮抗药，逆转肌松药

的残余作用70经验判断Head-liftfor5secondsmaximumnegativeinspiratorypressureof35cmH2OHand-gripEyesopenTongue-stretchVTVASPO271外

周神经刺激器72singletwitchstimulation,SS肌颤搐抑制90％以上可顺利完成气管插管和大部分腹部手术拮抗非去极化肌松药作用一般应在肌颤搐恢复到25％以上肌颤搐的幅度由25％恢复到75％的时间称恢复指数，反映肌肉收缩功能的恢复速率7

3tetanicstimulation,TS强直刺激引起的衰减与其后的易化用于鉴别肌松药阻滞性质和判断阻滞程度用于评定术后残余肌松时的常用频率为50Hz,持续刺激时间为5秒，如果不出现衰减，可作为临床

上随意肌张力恢复的指标74train-of-fourstimulation,TOFT4/T1的比值来评定阻滞程度有无衰减来确定阻滞性质T4、T3、T2和T1依次消失相当于单刺激肌颤搐抑制75％、80％、90％和100％T4／T1>0.75

时提示肌张力已基本恢复75posttetaniccount,PTC完全抑制了单刺激和四个成串刺激引起的肌颤搐时，可进一步用PTC来估计阻滞深度double-burststimulation，DBS术后

测定肌松消退及在恢复室判断残余肌松76监测的临床应用肝肾功能障碍或全身情况差、疾病严重以致肌松药的药代动力学或药效动力学可能受影响的病人重症肌无力和肌无力综合征等肌松药药效有异常者支气管哮喘、严重心脏病,及其他需要避免在手术结束时使用抗胆碱醋

酶药拮抗残余肌松的病人过度肥胖、严重胸部创伤、严重肺部疾病及呼吸功能受损已近临界水平、术后需充分恢复肌力的病人长时间应用或持续静脉滴注肌松药的病人77SummaryThemaingoalshouldb

etousethelowestpossibledosethatwillprovideadequaterelaxationforsurgeryStimulatingaperipheralnerveisthemostcommonlyadvocatedmethod

ofmonitoringneuromuscularfunctionclinicallyChoiceofRelaxantandTestingofRecovery78THANKS79